All posts by: Michael Zand

About Michael Zand

A Stem Cell Patch Could Heal Hearts Damaged By Cardiac Arrest – Futurism

Continue reading

2018-03-09 NEWS

Futurism

A Stem Cell Patch Could Heal Hearts Damaged By Cardiac Arrest
Futurism
But a team of researchers at the University of Cambridge’s Stem Cell Institute in the U.K. is developing an innovative way to repair heart tissue. The team’s solution doesn’t require a donor heart at all — instead, they’ve used stem cells to grow live

and more »

Continue reading

2018-03-09 NEWS

Madison.com

Here’s Why CRISPR Therapeutics AG Gained as Much as 14% Today
Madison.com
Shares of gene-editing pioneer CRISPR Therapeutics AG (NASDAQ: CRSP) dropped 14% today after the company announced full-year 2017 earnings and provided shareholders with a business update for what to expect in the year ahead. In the fourth quarter of
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial ResultsGlobeNewswire (press release)
Should You Consider CRISPR Therapeutics AG (CRSP) Based on Their Fundamentals?US Trade Media
UPDATE: CRISPR Therapeutics (CRSP) PT Raised to $59 at Barclays, Street HighStreetInsider.com
Zacks
all 72 news articles »
Continue reading

2018-03-09 NEWS

GlobeNewswire (press release)

Here’s Why CRISPR Therapeutics AG Gained as Much as 14% Today
Motley Fool
Shares of gene-editing pioneer CRISPR Therapeutics AG (NASDAQ:CRSP) dropped 14% today after the company announced full-year 2017 earnings and provided shareholders with a business update for what to expect in the year ahead. In the fourth quarter of
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial ResultsGlobeNewswire (press release)
CRISPR Therapeutics AG (NASDAQ:CRSP): Financial Strength AnalysisSimply Wall St
Should You Consider CRISPR Therapeutics AG (CRSP) Based on Their Fundamentals?US Trade Media
Zacks
all 73 news articles »
Continue reading

2018-03-09 NEWS

Emerging Advances for Immunotherapy in Urothelial Cancer
OncLive
Jonathan Rosenberg, MD: These are very exciting times—in the treatment of advanced bladder cancer and even in non–muscle invasive bladder cancer. We have a whole new therapeutic armamentarium that we’re understanding how to better use in this disease

Continue reading

2018-03-09 NEWS

Improving Responses to Immunotherapy in Bladder Cancer
OncLive
There are many reasons why a tumor may not respond to immunotherapy. It may range from the fact that there are not sufficient antigens to the fact that the antigens are not presented or that the immune cells can’t get into the tumor. Or even if they